Leukemia Podcasts

HealthTree Podcasts for Leukemia features in-depth interviews with Leukemia experts. These programs are a deep dive into a single topic about Leukemia and help patients understand the latest in research and ongoing clinical trials.

podcasts

May 12, 2025 / 12:00PM EDT

Episode 4: Clinical Trials: Myths, Facts, and What Patients Need to Know

play_circle_filled Listen to Episode

podcasts

May 05, 2025 / 12:00PM EDT

Episode 3: Young Adult AML: Understanding the Gaps & Closing Them

play_circle_filled Listen to Episode

podcasts

Apr 28, 2025 / 12:00PM EDT

Episode 2: Fighting AML in Young Patients: New Research & the Future of CAR-T

play_circle_filled Listen to Episode

Episode 1: When Should Treatment Start? What AML Patients Need to Know

Apr 21, 2025

Apr 21, 2025 / 12:00PM EDT

Adult AML Chapter

What are BTK Degraders? with Joanna Rhodes, MD

Apr 04, 2025

Apr 04, 2025 / 10:00AM EDT

Adult CLL Chapter

Unlocking New Treatment Strategies for Chronic Myelomonocytic Leukemia: Pacritinib and Azacitidine in Clinical Trial

Jan 10, 2025

Jan 10, 2025 / 10:00AM EST

HealthTree Podcast for CMML

Menin Inhibitors 101 with Dr. Joshua Zeidner

Jul 09, 2024

Jul 09, 2024 / 05:00PM EDT

Adult AML Chapter

A Personalized CLL Vaccine: NeoVax with Inhye Ahn, MD Dana-Farber Cancer Institute

May 10, 2024

May 10, 2024 / 02:30PM EDT

Adult CLL Chapter

Reducing Relapse Risk After Transplant Using Jakafi With Gabriela Hobbs, MD, Massachusetts General Hospital

Oct 05, 2022

Oct 05, 2022 / 01:30PM EDT

HealthTree Podcast for AML

Expanding the Use of Ivosidenib (Tibsovo) In Newly Approved Combination For IDH1-Mutated AML with Eytan Stein, MD, Memorial Sloan Kettering

Aug 24, 2022

Aug 24, 2022 / 11:00AM EDT

HealthTree Podcast for AML

Digging Deeper Into the TP53 Mutation in AML with Rory Shallis, MD, Yale New Haven Hospital

Jul 14, 2022

Jul 14, 2022 / 11:00AM EDT

HealthTree Podcast for AML

Weighing FLT3 Inhibitor Options with Dr. Jane Liesveld, University of Rochester

Jun 29, 2022

Jun 29, 2022 / 02:00PM EDT

HealthTree Podcast for AML

Attacking AML Cells with a New Immunotherapy Infusion with Kendra Sweet, MD, Moffitt Cancer Center

Jun 09, 2022

Jun 09, 2022 / 01:00PM EDT

HealthTree Podcast for AML

Killing AML Cells with Magrolimab, a New Immunotherapy Option, with Dr. Joseph Jurcic

May 26, 2022

May 26, 2022 / 11:00AM EDT

HealthTree Podcast for AML

Targeting FLT3 Positive AML with New & Improved Therapies with Dr. Margaret Kasner

Feb 07, 2022

Feb 07, 2022 / 01:00PM EST

HealthTree Podcast for AML

AML Progress in 2021 and a Look to the Future with Dr. Eytan Stein

Feb 02, 2022

Feb 02, 2022 / 12:00PM EST

HealthTree Podcast for AML

The Latest in AML Treatment Advances: Where We Are and Where We're Going with James Blachly, MD, Ohio State University

Oct 25, 2021

Oct 25, 2021 / 02:00PM CDT

HealthTree Podcast for AML

Harnessing the Immune System in Relapsed/Refractory AML with Dr. John Reagan, Rhode Island Hospital

Sep 30, 2021

Sep 30, 2021 / 12:00PM CDT

HealthTree Podcast for AML

Progress Toward an All Oral Treatment for Newly Diagnosed Older Adults with AML with Gabriel Mannis, MD

Sep 13, 2021

Sep 13, 2021 / 03:00PM CDT

HealthTree Podcast for AML

podcasts

Apr. 21, 2025

Episode 1: When Should Treatment Start? What AML Patients Need to Know

play_circle_filled Listen to Episode

podcasts

Apr. 04, 2025

What are BTK Degraders? with Joanna Rhodes, MD

play_circle_filled Listen to Episode

podcasts

Jan. 10, 2025

Unlocking New Treatment Strategies for Chronic Myelomonocytic Leukemia: Pacritinib and Azacitidine in Clinical Trial

play_circle_filled Listen to Episode

podcasts

Jul. 09, 2024

Menin Inhibitors 101 with Dr. Joshua Zeidner

play_circle_filled Listen to Episode

podcasts

May. 10, 2024

A Personalized CLL Vaccine: NeoVax with Inhye Ahn, MD Dana-Farber Cancer Institute

play_circle_filled Listen to Episode

podcasts

Oct. 05, 2022

Reducing Relapse Risk After Transplant Using Jakafi With Gabriela Hobbs, MD, Massachusetts General Hospital

play_circle_filled Listen to Episode

podcasts

Aug. 24, 2022

Expanding the Use of Ivosidenib (Tibsovo) In Newly Approved Combination For IDH1-Mutated AML with Eytan Stein, MD, Memorial Sloan Kettering

play_circle_filled Listen to Episode

podcasts

Jul. 14, 2022

Digging Deeper Into the TP53 Mutation in AML with Rory Shallis, MD, Yale New Haven Hospital

play_circle_filled Listen to Episode

podcasts

Jun. 29, 2022

Weighing FLT3 Inhibitor Options with Dr. Jane Liesveld, University of Rochester

play_circle_filled Listen to Episode

podcasts

Jun. 09, 2022

Attacking AML Cells with a New Immunotherapy Infusion with Kendra Sweet, MD, Moffitt Cancer Center

play_circle_filled Listen to Episode

podcasts

May. 26, 2022

Killing AML Cells with Magrolimab, a New Immunotherapy Option, with Dr. Joseph Jurcic

play_circle_filled Listen to Episode

podcasts

Feb. 07, 2022

Targeting FLT3 Positive AML with New & Improved Therapies with Dr. Margaret Kasner

play_circle_filled Listen to Episode

podcasts

Feb. 02, 2022

AML Progress in 2021 and a Look to the Future with Dr. Eytan Stein

play_circle_filled Listen to Episode

podcasts

Oct. 25, 2021

The Latest in AML Treatment Advances: Where We Are and Where We're Going with James Blachly, MD, Ohio State University

play_circle_filled Listen to Episode

podcasts $Harnessing the Immune System in Relapsed/Refractory AML with Dr. John Reagan, Rhode Island Hospital$

Sep. 30, 2021

Harnessing the Immune System in Relapsed/Refractory AML with Dr. John Reagan, Rhode Island Hospital

play_circle_filled Listen to Episode

podcasts

Sep. 13, 2021

Progress Toward an All Oral Treatment for Newly Diagnosed Older Adults with AML with Gabriel Mannis, MD

play_circle_filled Listen to Episode

Leukemia Podcasts

Episode 4: Clinical Trials: Myths, Facts, and What Patients Need to Know

Episode 3: Young Adult AML: Understanding the Gaps & Closing Them

Episode 2: Fighting AML in Young Patients: New Research & the Future of CAR-T

Episode 1: When Should Treatment Start? What AML Patients Need to Know

What are BTK Degraders? with Joanna Rhodes, MD

Unlocking New Treatment Strategies for Chronic Myelomonocytic Leukemia: Pacritinib and Azacitidine in Clinical Trial

Menin Inhibitors 101 with Dr. Joshua Zeidner

A Personalized CLL Vaccine: NeoVax with Inhye Ahn, MD Dana-Farber Cancer Institute

Reducing Relapse Risk After Transplant Using Jakafi With Gabriela Hobbs, MD, Massachusetts General Hospital

Expanding the Use of Ivosidenib (Tibsovo) In Newly Approved Combination For IDH1-Mutated AML with Eytan Stein, MD, Memorial Sloan Kettering

Digging Deeper Into the TP53 Mutation in AML with Rory Shallis, MD, Yale New Haven Hospital

Weighing FLT3 Inhibitor Options with Dr. Jane Liesveld, University of Rochester

Attacking AML Cells with a New Immunotherapy Infusion with Kendra Sweet, MD, Moffitt Cancer Center

Killing AML Cells with Magrolimab, a New Immunotherapy Option, with Dr. Joseph Jurcic

Targeting FLT3 Positive AML with New & Improved Therapies with Dr. Margaret Kasner

AML Progress in 2021 and a Look to the Future with Dr. Eytan Stein

The Latest in AML Treatment Advances: Where We Are and Where We're Going with James Blachly, MD, Ohio State University

Harnessing the Immune System in Relapsed/Refractory AML with Dr. John Reagan, Rhode Island Hospital

Progress Toward an All Oral Treatment for Newly Diagnosed Older Adults with AML with Gabriel Mannis, MD

Episode 1: When Should Treatment Start? What AML Patients Need to Know

What are BTK Degraders? with Joanna Rhodes, MD

Unlocking New Treatment Strategies for Chronic Myelomonocytic Leukemia: Pacritinib and Azacitidine in Clinical Trial

Menin Inhibitors 101 with Dr. Joshua Zeidner

A Personalized CLL Vaccine: NeoVax with Inhye Ahn, MD Dana-Farber Cancer Institute

Reducing Relapse Risk After Transplant Using Jakafi With Gabriela Hobbs, MD, Massachusetts General Hospital

Expanding the Use of Ivosidenib (Tibsovo) In Newly Approved Combination For IDH1-Mutated AML with Eytan Stein, MD, Memorial Sloan Kettering

Digging Deeper Into the TP53 Mutation in AML with Rory Shallis, MD, Yale New Haven Hospital

Weighing FLT3 Inhibitor Options with Dr. Jane Liesveld, University of Rochester

Attacking AML Cells with a New Immunotherapy Infusion with Kendra Sweet, MD, Moffitt Cancer Center

Killing AML Cells with Magrolimab, a New Immunotherapy Option, with Dr. Joseph Jurcic

Targeting FLT3 Positive AML with New & Improved Therapies with Dr. Margaret Kasner

AML Progress in 2021 and a Look to the Future with Dr. Eytan Stein

The Latest in AML Treatment Advances: Where We Are and Where We're Going with James Blachly, MD, Ohio State University

Harnessing the Immune System in Relapsed/Refractory AML with Dr. John Reagan, Rhode Island Hospital

Progress Toward an All Oral Treatment for Newly Diagnosed Older Adults with AML with Gabriel Mannis, MD

Trending Articles

How Race, Income, and Access to Care impact AML Outcomes

Understanding Secondary Cancer Risks in CLL: Signs, Screening, and Prevention

FDA Approves Simpler Way to Take Zanubrutinib (Brukinsa)

Leukemia Podcasts

Episode 4: Clinical Trials: Myths, Facts, and What Patients Need to Know

Episode 3: Young Adult AML: Understanding the Gaps & Closing Them

Episode 2: Fighting AML in Young Patients: New Research & the Future of CAR-T

Episode 1: When Should Treatment Start? What AML Patients Need to Know

What are BTK Degraders? with Joanna Rhodes, MD

Unlocking New Treatment Strategies for Chronic Myelomonocytic Leukemia: Pacritinib and Azacitidine in Clinical Trial

Menin Inhibitors 101 with Dr. Joshua Zeidner

A Personalized CLL Vaccine: NeoVax with Inhye Ahn, MD Dana-Farber Cancer Institute

Reducing Relapse Risk After Transplant Using Jakafi With Gabriela Hobbs, MD, Massachusetts General Hospital

Expanding the Use of Ivosidenib (Tibsovo) In Newly Approved Combination For IDH1-Mutated AML with Eytan Stein, MD, Memorial Sloan Kettering

Digging Deeper Into the TP53 Mutation in AML with Rory Shallis, MD, Yale New Haven Hospital

Weighing FLT3 Inhibitor Options with Dr. Jane Liesveld, University of Rochester

Attacking AML Cells with a New Immunotherapy Infusion with Kendra Sweet, MD, Moffitt Cancer Center

Killing AML Cells with Magrolimab, a New Immunotherapy Option, with Dr. Joseph Jurcic

Targeting FLT3 Positive AML with New & Improved Therapies with Dr. Margaret Kasner

AML Progress in 2021 and a Look to the Future with Dr. Eytan Stein

The Latest in AML Treatment Advances: Where We Are and Where We're Going with James Blachly, MD, Ohio State University

Harnessing the Immune System in Relapsed/Refractory AML with Dr. John Reagan, Rhode Island Hospital

Progress Toward an All Oral Treatment for Newly Diagnosed Older Adults with AML with Gabriel Mannis, MD

Episode 1: When Should Treatment Start? What AML Patients Need to Know

What are BTK Degraders? with Joanna Rhodes, MD

Unlocking New Treatment Strategies for Chronic Myelomonocytic Leukemia: Pacritinib and Azacitidine in Clinical Trial

Menin Inhibitors 101 with Dr. Joshua Zeidner

A Personalized CLL Vaccine: NeoVax with Inhye Ahn, MD Dana-Farber Cancer Institute

Reducing Relapse Risk After Transplant Using Jakafi With Gabriela Hobbs, MD, Massachusetts General Hospital

Expanding the Use of Ivosidenib (Tibsovo) In Newly Approved Combination For IDH1-Mutated AML with Eytan Stein, MD, Memorial Sloan Kettering

Digging Deeper Into the TP53 Mutation in AML with Rory Shallis, MD, Yale New Haven Hospital

Weighing FLT3 Inhibitor Options with Dr. Jane Liesveld, University of Rochester

Attacking AML Cells with a New Immunotherapy Infusion with Kendra Sweet, MD, Moffitt Cancer Center

Killing AML Cells with Magrolimab, a New Immunotherapy Option, with Dr. Joseph Jurcic

Targeting FLT3 Positive AML with New & Improved Therapies with Dr. Margaret Kasner

AML Progress in 2021 and a Look to the Future with Dr. Eytan Stein

The Latest in AML Treatment Advances: Where We Are and Where We're Going with James Blachly, MD, Ohio State University

Harnessing the Immune System in Relapsed/Refractory AML with Dr. John Reagan, Rhode Island Hospital

Progress Toward an All Oral Treatment for Newly Diagnosed Older Adults with AML with Gabriel Mannis, MD

Trending Articles

How Race, Income, and Access to Care impact AML Outcomes

Understanding Secondary Cancer Risks in CLL: Signs, Screening, and Prevention

FDA Approves Simpler Way to Take Zanubrutinib (Brukinsa)

Get the Latest Leukemia Updates, Delivered to You.